Genitourinary Drugs Market Size to Hit $68.51 Billion by 2030, at a 3.47% CAGR – Comprehensive Research Report by Facts & Factors

The global genitourinary drugs market size was valued at USD 32 billion in 2021 and is expected to surpass USD 68.51 billion by 2030, registering a CAGR of 3.47% during the forecast period (2022- 2030), as highlighted in a report published by Facts & Factors. The key market players are listed in the report with their sales, revenues and strategies are Eli Lilly and Company, AstraZeneca, Ionis Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc., and others.

Washington, D.C., Jan. 24, 2023 (GLOBE NEWSWIRE) — Facts and Factors has published a new research report titled “Genitourinary Drugs Market Size, Share, Growth Analysis Report By Product (Hormonal Therapy, Urological, and Others), By Disease (Erectile Dysfunction, Urinary Tract Infections, Hematuria, and Others), By End-User (Super Specialty Clinics, Hospitals, and Others), and By Region – Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022–2030” in its research database.

“According to the latest research study, the demand of global Genitourinary Drugs Market size & share was valued at approximately USD 32 billion in 2021. The market is expected to grow above a CAGR of 3.47% and is anticipated to reach over USD 68.51 billion by 2030.”

Genitourinary Drugs Market Overview:

Genitourinary drugs are used for the treatment of diseases related to the reproductive organs and the urinary system. These organs are developed from the intermediate mesoderm and the reproductive system is also known as the genital system. It is made of anatomical organs that involve sexual reproduction. Other non-living substances like hormones, fluids, and pheromones are also termed important accessories in the reproductive system.

Some of the most common types of concerns found in the women population include endometriosis which directly impacts the uterus of the woman. Other concerns like uterine fibroids, gynecological cancer, HIV / AIDS, interstitial cystitis, polycystic ovary syndrome, sexually transmitted diseases, and sexual violence are treated using genitourinary drugs. Male reproductive organs may suffer from diseases like erectile dysfunction, penis disorders, genital warts, circumcision, genital herpes, and gonorrhea. Urinary system medical concerns that can be cured using genitourinary drugs along with other subscription drugs include cases of kidney stones, urinalysis, ostomy, bladder cancer, and urinary incontinence.

Get a Free Sample PDF of this Research Report for more Insights with Table of Content, Research Methodology, and Graphs – https://www.fnfresearch.com/sample/genitourinary-drugs-market

(A free sample of this report is available upon request; please contact us for more information.)

Our Free Sample Report Consists of the Following:

• Introduction, Overview, and in-depth industry analysis are all included in the updated report.
• About 216+ Pages Research Report (Including Recent Research)
• Provide detailed chapter-by-chapter guidance on Request
• Updated Regional Analysis with Graphical Representation of Size, Share, and Trends
• Includes Tables and figures have been updated
• The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, Revenue Analysis, SWOT Analysis, Historic and Forecast Growth, Porter’s 5 Forces Analysis
• Facts and Factors research methodology

Key Insights from Primary Research

• As per the analysis, the genitourinary drugs market is likely to grow above a CAGR of around 3.47% between 2022 and 2030.
• The Genitourinary Drugs market size was worth around US$ 32 billion in 2021 and is estimated to hit approximately US$ 68.51 billion by 2030. Due to a variety of driving factors, the market is predicted to rise at a significant rate.
• The market is projected to grow at a significant rate due to the growing investments in research & development in the healthcare field
• Based on product segmentation, hormonal therapy was predicted to show maximum market share in the year 2021
• Based on end-user segmentation, hospitals were the leading end-users in 2021
• On the basis of region, North America was the leading revenue generator in 2021

Industry Growth Drivers

• Growing cases of ovarian and prostate cancer to drive market demand

The global genitourinary drugs market is projected to grow owing to the increasing research & development of effective and versatile drugs that can efficiently cure diseases related to reproductive organs and urinary systems. The greatest advancements are currently being made in the treatment of prostate cancer which starts and spreads across the male reproductive organ. It is one of the leading forms of cancer in men and has a high fatality rate. However, the growing number of United States Food and Drugs Administration approval as well as ongoing phase-wise research of newer drugs is projected to help the global market witness high CAGR.

Various multinational corporations are working in collaboration with pharmaceutical giants to enter remote markets and cater to a larger section of the population. These efforts will help the global market players expand their consumer database which in turn is projected to positively impact the global market sales value. The healthcare sector across regions is witnessing a surge in the number of investments since healthcare infrastructure is a leading indicator of economic growth and one of the key essentials for any economy to compete with the superpowers. Most of the investments are directed toward research activities. The increasing number of collaborative research is another contributing factor to the global market growth trajectory.

Restraints

• Increasing expiration rate of patents to restrict market expansion

There may be certain growth restrictions in the coming years owing to the potential side effects associated with the use of genitourinary drugs. As these medicines are high in power, they should only be consumed under prescription by authorized medical professionals. Long-term exposure to drugs in untapped conditions can lead to severe health side effects which have already been observed in various cases. Other factors like consulting accurate and ethical trial processes may also act as a barrier during the global market growth as companies may fail to follow the laid down protocols to avoid non-approval from regulatory bodies.

Opportunities

• Growing number of reproduction-related medical assistance to provide growth opportunities

A growing number of reproduction-related medical assistance may provide growth opportunities while the presence of counterfeit products is projected to challenge market growth.

Directly Purchase a copy of the report with TOC @ https://www.fnfresearch.com/buynow/su/genitourinary-drugs-market

Competitive Players

The report contains qualitative and quantitative research on the global genitourinary drugs market, as well as detailed insights and development strategies employed by the leading competitors. The report also provides an in-depth analysis of the market’s main competitors, as well as information on their competitiveness.

Some of the main players in the global Genitourinary Drugs market include;

• EliLillyandCompany
• AstraZeneca
• IonisPharmaceuticals
• PfizerInc.
• GlaxoSmithKlineplc

Browse the full “Genitourinary Drugs Market Size, Share, Growth Analysis Report By Product (Hormonal Therapy, Urological, and Others), By Disease (Erectile Dysfunction, Urinary Tract Infections, Hematuria, and Others), By End-User (Super Specialty Clinics, Hospitals, and Others), and By Region – Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022–2030” Report at https://www.fnfresearch.com/genitourinary-drugs-market

Genitourinary Drugs Market: Segmentation Analysis

The global genitourinary drugs market is segmented based on product, disease, end-user, and region

Based on disease, the global market divisions are erectile dysfunction, urinary tract infections, hematuria, and others. The global market was led by the other segment in 2021 in which treatment for prostate cancer led the segmental growth owing to growing interest and research toward finding a cure for the disease. A lot of the patients suffering from this type of cancer succumb to the disease without any show of symptoms and hence it is important to conduct extensive research and spread awareness amongst the men population about the disease. Prostate cancer is the 4th most common type of tumor that is detected across the globe.

Based on end-user, the global market divisions are super specialty clinics, hospitals, and others. Although doctors generally recommend critical cases to specialty clinics because they have more expertise, the hospital segment dominated the global market growth in 2021. Hospitals are responsible for providing primary care and only if the case is extremely rare, the cases are moved to specialty units. Urinary tract infection is known to affect nearly 3% of the global men population.

Regional Analysis:

• North America to lead with the highest CAGR

North America is anticipated to lead the global genitourinary drugs market owing to the presence of some of the biggest brands in the pharmaceutical industry including Pfizer and Johnsons and Johnsons. The companies invest heavily in developing new products by adopting advanced technologies and techniques which is expected to propel the regional market growth.

Asia-Pacific is anticipated to register a high CAGR due to the growing population and a subsequent number of medical cases. Increasing accessibility for the treatment of diseases associated with reproductive systems may help generate higher revenue. As estimated, around 18% of couples in Japan underwent infertility treatment or testing in 2021.

Have Any Query? Ask Our Experts: https://www.fnfresearch.com/inquiry/genitourinary-drugs-market

Recent Industry Developments:

• In October 2022, Pfizer, a leading pharmaceutical giant, announced the positive results obtained while testing the phase 3 TALAPRO-2 trial of TALZENNA® which is used as an inhibitor for poly ADP-ribose polymerase
• In November 2022, the United States Food and Drugs Administration department approved the abbreviated application of Leuprolide Acetate Injections to be used in advanced cases of prostate cancer

Report Scope:

Request for Customization on this Report as per your requirements – https://www.fnfresearch.com/customization/genitourinary-drugs-market

(We tailor your report to meet your specific research requirements. Inquire with our sales team about customising your report.)

The global genitourinary drugs market is segmented as follows:

By Product 

• Hormonal Therapy
• Urological
• Others

By Disease 

• Erectile Dysfunction
• Urinary Tract Infections
• Hematuria
• Others

By End-User 

• Super Specialty Clinics
• Hospitals
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Southeast Asia
• The Middle East & Africa
  • GCC
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

Request Your Free Sample Report of the Global Genitourinary Drugs Market @ https://www.fnfresearch.com/sample/genitourinary-drugs-market

Key Offerings:

• Market Size, Trends, & Forecast by Revenue | 2022−2030
• Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities
• Market Segmentation – A detailed analysis by Product, Disease, End-User, and Region
• Competitive Landscape – Top Key Vendors and Other Prominent Vendors

Browse Other Related Research Reports from Facts & Factors

• Asthma Drugs Market Size, Share, Growth Analysis Report By Mode Of Administration (Injections, Inhalers, Tablets & Capsules, Sprays & Powders, and Liquids), By Medication (Long-Term Control Medications, and Quick Relief Medications), By Application (Adults, Pediatric, and Adolescent), By Source (Generic, and Environmental), and By Region – Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030
• Antihypertensive Drugs Market Size, Share, Growth Analysis Report By Disease Source (Secondary Hypertension and Primary Hypertension), By Therapeutics (Angiotensin Receptor Blockers (ARBs), Diuretics, Beta Blockers, Angiotensin Converting Enzyme (ACE), Calcium Channel Blockers, Alpha Blockers, Vasodilators, and Renin Inhibitors), By End-Users (Clinics, Hospitals, and Homecare), and By Region – Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030
• Musculoskeletal Disorders Drugs Market Size, Share, Growth Analysis Report By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Drug Stores, and Others), By Disease Type (Muscle Relaxants, Rheumatoid Arthritis, and Others), By Classification (Generic Drugs, and Branded Drugs), By Administration Route (Parenteral, Oral, and Others), and By Region – Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030
• Erectile Dysfunction Drugs Market by Drug Type (Sildenafil Citrate (Viagra), Vardenafil (Levitra/ Staxyn), Tadalafil (Cialis), Udenafil (Zydena), Lodenafil Carbonate (Helleva), Stendra/ Spedra (Avanafil), Mirodenafil (Mvix), and Others), by Mode of Administration (Oral Medications, Topical Medications, Injections, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Sales): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026
• Antimalarial Drugs Market Size, Share, Growth Analysis Report By Drug Class (Quinine, Chloroquine, Proguanil, Mefloquine, Pyrimethamine, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce & Other Distribution Channel), and By Region – Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028
• Anticoagulant Drugs Market Size, Share, Growth Analysis Report By Drug Class (Heparins, Factor Xa Inhibitor, Warfarin, Direct Thrombin Inhibitor, and Others), By Route of Administration (Oral and Injectable), By Application (Atrial Fibrillation/Flutter, Venous Thromboembolism, Coronary Heart Disease, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region – Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028

About Facts & Factors:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.

Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:

Facts & Factors

USA: +1 347 690-0211 | UK: +44 2032 894158 | Japan: +81 50 5806 9039 | India: +91 73877 19999

Email: sales@fnfresearch.com | Web: https://www.fnfresearch.com

Follow Us on – LinkedIn | Twitter | Facebook

 Also Read Our Blogs:

• http://fnfnewsblog.com
• https://www.fnfresearch.com/blog/

• Author
• Recent Posts

GlobeNewswire

GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Latest posts by GlobeNewswire (see all)

• Sound Financial Bancorp, Inc. Q4 2022 Results - January 27, 2023
• Sovos Brands Intermediate, Inc. Issues Allergy Alert on Undeclared Egg in Rao’s Slow Simmered Soup, Labeled as Chicken & Gnocchi but Containing Vegetable Minestrone - January 27, 2023
• Goal Acquisitions Corp. Issues Letter to Shareholders Regarding Proposed Combination with Digital Virgo - January 27, 2023